Article

Convalescent Plasma-Mediated Resolution of Covid-19 in Humoral Immunodeficiency

2020-09-05

Abstract excerpt

Convalescent plasma (CP) is widely used to treat Covid-19, but without formal evidence of efficacy. Here, we report the beneficial effects of CP in a severely ill Covid-19 patient with prolonged pneumonia and advanced chronic lymphocytic leukemia (CLL), who was unable to generate an antiviral antibody response of her own. On day-33 after becoming symptomatic, the patient received CP containing high-titer (ID 50...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f019658f-ae6e-56b6-8d5c-c336a67d2857
DOI: 10.2139/ssrn.3687028

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Convalescent Plasma-Mediated Resolution of Covid-19 in Humoral ImmunodeficiencyDOI 10.2139/ssrn.3687028Read

COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic reviewSemantic proximity Read

Functional Antibodies in COVID-19 Convalescent PlasmaSemantic proximity Read

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide EvidenceSemantic proximity Read

COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacySemantic proximity Read

Administration of vaccine-boosted COVID-19 convalescent plasma to SARS-CoV-2 infected hamsters decreases virus replication in lungs and hastens resolution of the infection despite transiently enhancing disease and lung pathologySemantic proximity Read

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal AntibodiesSemantic proximity Read

COVID-19 convalescent plasma to treat hospitalised COVID-19 patients with or without underlying immunodeficiency: a randomized trialSemantic proximity Read

Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell depleting agentsSemantic proximity Read

Inflammatory Markers and Auto-Abs to Type I IFNs in COVID-19 Convalescent PlasmaSemantic proximity Read

Outcomes of Convalescent Plasma with Defined High- Versus Lower-Neutralizing Antibody Titers Against SARS-CoV-2 Among Hospitalized Patients: Coronavirus Inactivating Plasma (CoVIP), Double-Blind Phase 2 StudySemantic proximity Read

Atypical COVID-19 dynamics in a patient with Mantle Cell Lymphoma Exposed to RituximabSemantic proximity Read

Convalescent serum lines up as first-choice treatment for coronavirusSemantic proximity Read